Aptevo Therapeutics Inc.APVONASDAQ
Loading
SG&A Expense Growth Recovery in ProgressRecovering
Percentile Rank27
Studio
Year-over-Year Change

Year-over-year SG&A expense growth

Percentile
P27
Within normal range
vs 3Y Ago
-2.5x
Contraction
Streak
1 yr
Consecutive growthRecovering
PeriodValue
2024-13.14%
2023-15.15%
2022-5.61%
20215.35%
2020-0.09%
2019-50.36%
2018-18.63%
2017-10.58%
2016-10.17%
201525.56%